Hims & Hers Health (NYSE:HIMS) Stock Price Down 5.1% After Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS) fell 5.1% on Wednesday after an insider sold shares in the company. The company traded as low as $21.81 and last traded at $22.33. 6,071,314 shares were traded during trading, a decline of 35% from the average session volume of 9,362,292 shares. The stock had previously closed at $23.53.

Specifically, COO Melissa Baird sold 58,750 shares of Hims & Hers Health stock in a transaction dated Monday, November 18th. The stock was sold at an average price of $21.04, for a total transaction of $1,236,100.00. Following the completion of the transaction, the chief operating officer now owns 630,166 shares in the company, valued at approximately $13,258,692.64. This trade represents a 8.53 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, CFO Oluyemi Okupe sold 142,886 shares of the firm’s stock in a transaction dated Wednesday, November 13th. The stock was sold at an average price of $29.93, for a total value of $4,276,577.98. Following the sale, the chief financial officer now directly owns 112,186 shares in the company, valued at approximately $3,357,726.98. This trade represents a 56.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here.

Analyst Upgrades and Downgrades

Several equities research analysts have commented on the company. Piper Sandler restated a “neutral” rating and issued a $21.00 price objective (up previously from $18.00) on shares of Hims & Hers Health in a research report on Tuesday, November 5th. Deutsche Bank Aktiengesellschaft increased their price target on shares of Hims & Hers Health from $23.00 to $27.00 and gave the stock a “hold” rating in a report on Wednesday, November 6th. Bank of America cut shares of Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price objective for the company from $32.00 to $18.00 in a report on Thursday, November 14th. Canaccord Genuity Group increased their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Tuesday, November 5th. Finally, TD Cowen restated a “buy” rating and issued a $28.00 price target on shares of Hims & Hers Health in a research note on Wednesday. One equities research analyst has rated the stock with a sell rating, eight have issued a hold rating and seven have issued a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $20.71.

Hims & Hers Health Stock Up 9.8 %

The company has a 50-day moving average of $20.37 and a 200 day moving average of $19.12. The stock has a market capitalization of $5.23 billion, a PE ratio of 54.40 and a beta of 1.06.

Hims & Hers Health (NYSE:HIMS) last announced its earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.06 by $0.26. The company had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm’s quarterly revenue was up 77.1% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.04) EPS. As a group, equities analysts predict that Hims & Hers Health, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Trading of Hims & Hers Health

A number of hedge funds have recently bought and sold shares of the business. Neo Ivy Capital Management purchased a new stake in shares of Hims & Hers Health in the third quarter valued at approximately $1,252,000. Geode Capital Management LLC boosted its stake in Hims & Hers Health by 12.7% during the third quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after buying an additional 482,177 shares during the last quarter. Barclays PLC grew its holdings in Hims & Hers Health by 9.7% in the 3rd quarter. Barclays PLC now owns 308,363 shares of the company’s stock valued at $5,680,000 after buying an additional 27,231 shares in the last quarter. Y Intercept Hong Kong Ltd increased its stake in shares of Hims & Hers Health by 312.6% in the 3rd quarter. Y Intercept Hong Kong Ltd now owns 134,018 shares of the company’s stock worth $2,469,000 after acquiring an additional 101,536 shares during the last quarter. Finally, MML Investors Services LLC purchased a new position in shares of Hims & Hers Health during the 3rd quarter worth $197,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.